pharmiweb.com today | 28 May 2018
Eisai and Merck Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib in First-Line Unresectable Hepatocellular Carcinoma
Eisai Inc. and Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has extended the action date for the supplemental New Drug Application (sNDA) for lenvatinib for the potential first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
The FDA has indicated that the extension of the Prescription Drug User Fee Act (PDUFA) date is needed to allow additional time for review of the application. The agency expects to complete the review on or before August 24, 2018, thus extending the target action date by a standard extension period of three months from the original PDUFA action date of May 24, 2018....
Eisai, as the marketing authorization holder, is working closely with the FDA to support the continued review of this application.
Lenvatinib (available as LENVIMA®) is approved by the U.S. FDA for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. Lenvatinib is also approved by the U.S. FDA in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.
show moreshow less
Top Jobs
- Patient Engagement Project Manager - Herts.
Welwyn Garden City
- Program Director
Uxbridge, England,United Kingdom
- Clinical Contracts Associate
London, United Kingdom
- Advisory Consultant
Wimbledon
- Regulatory Drug Device Expert ** Global Strategy Lead role “GRL” ** Take devices to the New Frontiers ‘Pill Tech’ solutions ** 2 East Coast Locations
East Coast
- Quality Manager (EMA and ROW) ** Ghent / Antwerpen / Brussels West *** Growing and dynamic company, QA GMP NPI type role
Ghent, Antwerpen, Brussels West
- Client Project Manager
Amersham, Buckinghamshire
- *** Regulatory Policy and Intelligence Director *** UK W London or M4 OR 2/3 different EU locations
Multiple UK / EU Locations
- OPTION SUISSE ** Regulatory CMC Director *** Pure mAbs & Team Management role ** Development & Marketed, US and Europe & Int’l Majors?
Switzerland
- Belgium - Drug Safety Associate - Career Roles in PV/Drug Safety - Ghent, Antwerp – Receive great training and development…!!!
Gent Area, Belgium
show moreshow less
Latest Poll
If you are considering a job change, what are the main reasons?
Pharmiweb.com RSS Feeds 
